The Short Answer on a Generic for Farxiga
Farxiga (dapagliflozin) is a widely prescribed SGLT2 inhibitor used to treat type 2 diabetes, heart failure, and chronic kidney disease. With a retail price of approximately $550 to $620 per month, many patients are asking: is there a generic for Farxiga? As of early 2026, no FDA-approved generic version of dapagliflozin is available in the United States. AstraZeneca, the manufacturer, holds patent protections that have so far prevented generic entry.
That does not mean you are without options. While waiting for a generic, several strategies can significantly reduce what you pay for Farxiga. This guide covers the current patent landscape, when a generic might arrive, and every available savings program in the meantime.
Why There Is No Generic Yet
Farxiga received FDA approval in January 2014 for type 2 diabetes. It later gained additional approvals for heart failure (May 2020) and chronic kidney disease (April 2021), broadening its patient base substantially. AstraZeneca holds multiple patents covering dapagliflozin’s compound, formulation, and methods of use.
The primary composition-of-matter patent for dapagliflozin was originally set to expire in 2020 but received a patent term extension. Additional patents in the Orange Book extend protection into the late 2020s. Several generic manufacturers have filed Abbreviated New Drug Applications (ANDAs) challenging some of these patents under Paragraph IV of the Hatch-Waxman Act, but litigation is ongoing.
Patent challenges and settlements in the pharmaceutical industry are complex and can change timelines unpredictably. Based on current patent listings and litigation activity, generic dapagliflozin could potentially become available between 2027 and 2029, though the exact date remains uncertain.
How Farxiga Works and Why It Is Popular
Understanding why so many patients take Farxiga helps explain the urgency around the generic question. Farxiga belongs to the SGLT2 inhibitor class, which works by preventing the kidneys from reabsorbing glucose back into the bloodstream. Instead, excess glucose is excreted in the urine, lowering blood sugar levels.
Beyond glucose control, SGLT2 inhibitors have demonstrated remarkable cardiovascular and renal benefits. The DAPA-HF trial, published in the New England Journal of Medicine, showed that Farxiga reduced the risk of cardiovascular death and hospitalization for heart failure by 26% compared to placebo. The DAPA-CKD trial showed a 39% reduction in the risk of kidney function decline, kidney failure, or death from renal or cardiovascular causes.
These landmark trials led to expanded FDA indications and inclusion in clinical guidelines from the American Diabetes Association, the American Heart Association, and the Kidney Disease: Improving Global Outcomes (KDIGO) organization. The result is a growing patient population that depends on Farxiga and is directly affected by its high cost.
Current Farxiga Pricing
Without insurance or a discount program, the average retail price for Farxiga 10mg (30 tablets) ranges from $550 to $620 at major U.S. pharmacies. Here is a snapshot of approximate pricing:
- CVS: $610
- Walgreens: $615
- Walmart: $580
- Costco: $530
- With GoodRx coupon: $470 to $540 depending on pharmacy and location
For patients taking Farxiga long-term, annual costs without assistance exceed $6,000. This makes savings programs essential for affordability.
How to Save on Farxiga Right Now
While the answer to “is there a generic for Farxiga” remains no, these strategies can meaningfully reduce your cost.
AstraZeneca Savings Card
AstraZeneca offers a copay savings card for commercially insured patients that can reduce the cost to as low as $0 per month, with a maximum annual benefit. The card is available at farxiga.com and is not valid for patients with government insurance (Medicare, Medicaid, TRICARE, VA). Eligible patients can enroll online or by calling AstraZeneca’s support line.
AZ&Me Patient Assistance Program
For uninsured patients or those who cannot afford Farxiga even with insurance, AstraZeneca’s AZ&Me program provides the medication at no cost. Eligibility typically requires U.S. residency, no prescription drug coverage (or inadequate coverage), and household income at or below 400% of the Federal Poverty Level (approximately $62,400 for an individual in 2026). Applications are available at azandmeapp.com or by calling 1-800-292-6363.
Prescription Discount Cards
GoodRx, RxSaver, and SingleCare offer coupons that can reduce Farxiga’s cash price by 10% to 20%. While the savings are more modest compared to what you would see with a generic, every dollar counts when you are paying out of pocket.
Medicare Part D Strategies
Medicare beneficiaries should ensure Farxiga is on their Part D plan’s formulary and placed on a tier they can afford. If it is on a non-preferred tier, request a formulary exception through your prescriber. The Extra Help (Low-Income Subsidy) program can reduce copays to $11.20 for brand-name drugs. The $2,000 annual out-of-pocket cap under the Inflation Reduction Act also limits total Part D spending.
340B Pharmacies
340B-eligible pharmacies purchase drugs from manufacturers at steep discounts mandated by federal law. If your healthcare provider participates in the 340B program, you may access Farxiga at a reduced cost.
Alternatives to Farxiga
If the cost of Farxiga is prohibitive and no savings program covers your situation, discuss alternatives with your doctor.
Other SGLT2 inhibitors: Jardiance (empagliflozin) is the closest therapeutic alternative. It has similar cardiovascular and renal benefits but is also brand-name with comparable pricing. Neither Jardiance nor Farxiga has a generic available as of 2026.
Older diabetes medications with generics: If you take Farxiga primarily for blood sugar control, your doctor might consider adding or switching to a generic medication like metformin ($4 to $10/month), glipizide ($4 to $15/month), or pioglitazone ($10 to $25/month). These do not provide the same cardiovascular or renal benefits as SGLT2 inhibitors, so the trade-off must be carefully evaluated.
GLP-1 receptor agonists: Drugs like Ozempic and Trulicity offer cardiovascular benefits but are also brand-name and expensive. Generic liraglutide may become available before generic dapagliflozin, depending on patent timelines.
Switching medications should never be done without medical guidance. If Farxiga was prescribed for heart failure or chronic kidney disease, the evidence supporting its use in those conditions is strong, and alternatives may not offer equivalent outcomes.
What to Expect When a Generic Arrives
When generic dapagliflozin eventually reaches the market, patients can expect significant price reductions. Based on historical patterns for brand-to-generic transitions, the first generic entrant typically prices at 20% to 30% below the brand. As additional manufacturers enter, prices often drop 80% to 90% within two to three years.
For a drug with a current retail price of $600, that could mean generic prices eventually falling to $60 to $120 per month. Combined with discount cards and insurance, out-of-pocket costs for generic dapagliflozin could be under $20 for many patients.
To stay informed about generic availability, periodically check the FDA’s Orange Book at fda.gov, which lists approved drug products and their generic status. Pharmacy and healthcare news sites also track major generic launches.
Frequently Asked Questions
When will a Farxiga generic be available?
Based on current patent protections and ongoing litigation, generic dapagliflozin could become available between 2027 and 2029. The exact date depends on the outcome of patent challenges filed by generic manufacturers. Settlements between AstraZeneca and generic companies could accelerate or delay this timeline.
Is there a generic for Jardiance?
No. Jardiance (empagliflozin), manufactured by Boehringer Ingelheim and Eli Lilly, also lacks a generic version as of 2026. Its patent situation is similar to Farxiga’s, with generic entry not expected until the late 2020s.
Can I import Farxiga from another country?
Importing prescription drugs from other countries is generally prohibited under U.S. federal law, though FDA enforcement for personal-use quantities is limited. Prices in Canada and other countries are typically lower, but the legality and safety of importation remain gray areas. Stick with FDA-approved sources whenever possible.
Is the AstraZeneca savings card available to everyone?
No. The savings card is limited to patients with commercial (private) health insurance. Patients covered by Medicare, Medicaid, TRICARE, or VA benefits are ineligible due to federal anti-kickback regulations. Those patients should explore the AZ&Me patient assistance program or Medicare Extra Help.
Manage Your Costs Until a Generic Arrives
The answer to “is there a generic for Farxiga” is not yet, but that does not mean you have to pay full price. Between AstraZeneca’s savings card, the AZ&Me patient assistance program, discount cards, and Medicare subsidies, most patients can find a path to more affordable treatment. Stay informed about patent developments, and when a generic does launch, work with your pharmacist to switch promptly. For more ways to reduce prescription and healthcare costs, explore our healthcare costs guide.